Quick Answer
InMed Pharmaceuticals Inc. reported Stockholders Equity of $13.43 million for fiscal year 2025.
InMed Pharmaceuticals Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $13.43M | +45.9% |
| 2024 | $9.21M | -23.9% |
| 2023 | $12.09M | +33.2% |
| 2022 | $9.08M | +23.1% |
| 2021 | $7.38M | +25.5% |
| 2020 | $5.88M | -58.7% |
| 2019 | $14.24M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $9.59M | +55.1% | -17.3% |
| September 30, 2025 | $11.59M | +38.1% | -13.7% |
| June 30, 2025 | $13.43M | +45.9% | +91.3% |
| March 31, 2025 | $7.02M | -36.8% | +13.6% |
| December 31, 2024 | $6.18M | -51.6% | -26.4% |
| September 30, 2024 | $8.40M | +187.7% | -8.8% |
| June 30, 2024 | $9.21M | -23.9% | -17.1% |
| March 31, 2024 | $11.10M | -10.4% | -13.1% |
- InMed Pharmaceuticals Inc. showed an increase of +45.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, InMed Pharmaceuticals Inc.’s stockholders equity has declined by 5.7% (from $14.24 million to $13.43 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: